Biopharmx Corp (NYSEAMERICAN:BPMX) saw a significant growth in short interest in the month of December. As of December 29th, there was short interest totalling 6,319,421 shares, a growth of 2.3% from the December 15th total of 6,178,513 shares. Based on an average trading volume of 2,712,891 shares, the days-to-cover ratio is presently 2.3 days. Currently, 6.0% of the shares of the stock are sold short.

In related news, Director Stephen Morlock bought 330,000 shares of the company’s stock in a transaction on Friday, November 24th. The stock was acquired at an average cost of $0.15 per share, for a total transaction of $49,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $0.20, for a total transaction of $59,278.80. The disclosure for this sale can be found here.

Shares of Biopharmx (NYSEAMERICAN:BPMX) opened at $0.12 on Friday. The firm has a market cap of $14.26, a P/E ratio of -0.44 and a beta of 1.33. Biopharmx has a 1-year low of $0.10 and a 1-year high of $0.90.

Several equities research analysts have issued reports on the stock. Maxim Group reiterated a “buy” rating and set a $1.50 target price on shares of Biopharmx in a research report on Friday, December 8th. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Biopharmx in a research report on Tuesday, September 19th.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.